Drug Profile
Serclutamab talirine - AbbVie
Alternative Names: ABBV-321Latest Information Update: 30 May 2022
Price :
$50
*
At a glance
- Originator AbbVie
- Class Antineoplastics; Benzodiazepines; Drug conjugates; Immunotoxins; Pyrroles
- Mechanism of Action DNA cross linking agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
- Preclinical Glioblastoma
Most Recent Events
- 30 May 2022 Serclutamab talirine is still in phase I development for Glioblastoma (Late-stage disease) in Australia, Israel and the US
- 08 Apr 2022 Preclinical trials in Glioblastoma in USA, prior to April 2022 (Parenteral)
- 08 Apr 2022 Pharmacodynamics data from a preclinical trial in Glioblastoma presented at the 113th Annual Meeting of the American Association for Cancer Research (AACR-2022)